Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Clinical and Experimental Immunology

• Publication date

  1995-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2249.1995.tb05572.xPMID 7882569PMCID PMC1534207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Attenuation of anti-Thy1 glomerulonephritis in the rat by anti-inflammatory platelet-inhibiting agents.

  1993cited by this paper
• Differential cytokine regulation by eicosanoids in T cells primed by contact sensitisation with TNP.

  1993cited by this paper
• Improvement in steroid and immunosuppressive drug resistant lupus nephritis by intravenous prostaglandin E1 therapy.

  1990cited by this paper
• Cyclooxygenase inhibition enhances rat interleukin 1 beta-induced growth of rat mesangial cells in culture.

  1990cited by this paper
• Regulation of human mesangial cell growth in culture by thromboxane A2 and prostacyclin.

  1990cited by this paper
• Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate. Physiological triggers and modulation by prostanoids.

  1989cited by this paper
• Age-associated changes in renal glomeruli of mice.

  1989cited by this paper
• The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide

  1987cited by this paper
• The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.

  1987cited by this paper
• The Role of Arachidonic Acid Metabolites in Mononuclear Phagocytic Cell Interactions

  1986cited by this paper
• Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4

  1985cited by this paper
• Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine.

  1983cited by this paper
• Treatment of murine immune complex glomerulonephritis with prostaglandin E2: dose--response of immune complex deposition, antibody synthesis, and glomerular damage.

  1983cited by this paper
• Murine serum glycoprotein gp70 behaves as an acute phase reactant

  1982cited by this paper
• Suppression of murine T-cell mitogenesis by metabolic products of arachidonic acid.

  1982cited by this paper
• Prostacyclin produced by the pregnant uterus in the dog may act as a circulating vasodepressor substance.

  1981cited by this paper
• Selective suppression of retroviral gp70-anti-gp70 immune complex formation by prostaglandin E1 in murine systemic lupus erythematosus

  1980cited by this paper
• Inhibition of polymorphonuclear leukocyte adherence by prostacyclin.

  1980cited by this paper
• Effect of prostaglandin E on immune complex nephritis in NZB/W mice.

  1979cited by this paper
• The Hemodynamic Effects of Prostaglandins in the Rat: Evidence for Important Species Variation in Renovascular Responses

  1979cited by this paper
• PGI2 and PGD2 effects on cyclic AMP and human T-cell mitogenesis.

  1979cited by this paper
• Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

  1978cited by this paper
• Prostaglandin E treatment of NZB/NZW mice.

  1977cited by this paper
• THE VIRAL ENVELOPE GLYCOPROTEIN OF MURINE LEUKEMIA VIRUS AND THE PATHOGENESIS OF IMMUNE COMPLEX GLOMERULONEPHRITIS OF NEW ZEALAND MICE

  1974cited by this paper
• The immunology and pathology of NZB mice.

  1968cited by this paper
• PATHOGENESIS OF THE GLOMERULONEPHRITIS OF NZB/W MICE

  1968cited by this paper
• NZB/NZW mice as a model of systemic lupus erythematosus.

  1966cited by this paper
• Immunochemical quantitation of antigens by single radial immunodiffusion.

  1965cited by this paper

• Clinical efficacy and safety of beraprost sodium in the treatment of nephrotic syndrome: A meta-analysis

  2023cites this paper
• Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

  2015cites this paper
• A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design

  2014cites this paper
• Long-term observation of renal function on combination therapy with prostaglandin and angiotensin-converting enzyme inhibitor for chronic kidney disease.

  2008cites this paper
• Therapeutics in Renal Disease: The Road Ahead for Antiproliferative Targets

  2005cites this paper
• Long-Term Renoprotective Effect of Combination Therapy with Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Patients with Chronic Renal Failure

  2005cites this paper
• Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model.

  2002cites this paper
• Remèdes à l'insuffisance rénale

  2000cites this paper
• Endothelial cell activation.

  1998cites this paper
• Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat.

  1998cites this paper
• Endothelial cell activation

  1998cites this paper
• Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats.

  1997cites this paper
• Bacterial superantigen enhances cytokine production by T-helper lymphocyte subset-2 cells and modifies glomerular lesions in experimental immunoglobulin a nephropathy

  1997cites this paper
• Macrophage‐colony stimulating factor (M‐CSF) enhances proteinuria and recruitment of macrophages into the glomerulus in experimental murine nephritis

  1996cites this paper